Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.86 USD | -1.79% | -2.18% | +63.89% |
10/05 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
09/05 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.89% | 169.8Cr | |
+34.44% | 5.08TCr | |
+0.65% | 4.28TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.95TCr | |
+10.95% | 2.61TCr | |
-21.65% | 1.91TCr | |
+8.77% | 1.31TCr | |
+27.51% | 1.22TCr | |
+24.54% | 1.21TCr |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics : Wedbush Adjusts Price Target on Edgewise Therapeutics to $31 From $35, Keeps Outperform Rating